



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cormwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Frir K. Steffe Linda F. Alcom Robert C. Millonig Lawrence B. Bugaisky Donald J. Featherstone Michael V. Messinger

Judith U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Heidi L. Kraus Albert L. Ferro\* Donald R. Banowit Jeffrey S. Weaver Kendrick P. Pattersor Vincent L. Capuano Eldora Ellison Floyd Thomas C. Fiala

Joseph S. Ostroff Frank R. Cottingham Christine M. Lhulier Rae Lynn P. Guest George S. Bardmesse Daniel A. Klein\* Jason D. Eisenberg Jason D. Eisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller\* LuAnne M. DeSantis Ann E. Summerfield Aric W. Ledford\* Helene C. Carlson Firmsthy A. Drede\* Timothy A. Doyle .. Longsworth Gordon\* Nicole D. Dretar

Ted J. Ebersole Registered Patent Agents • Karen R. Markowicz Aaron L. Schwartz Katrina Yujian Pei Quach Bryan L. Skelton Robert A. Schwartzman Teresa A. Colella Jeffrey S. Lundgren Victoria S. Rutherford Michelle K. Holoubek Robert H. DeSelms Simon J. Elliott

Julie A. Heider Mita Mukherjee Scott M. Woodhouse

<u>Of Counsel</u> Kenneth C. Bass III Evan R. Smith Marvin C. Guthrie

Admitted only in Maryland Admitted only in Virginia Practice Limited to Federal Agencies

October 28, 2004

WRITER'S DIRECT NUMBER: (202) 772-8560 INTERNET ADDRESS: RESMOND@SKGF.COM

Mail Stop RCE

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 09/942,583; Filed: August 31, 2001 **Neisserial Vaccine Compositions and Methods** 

Inventors:

ROBINSON et al.

Our Ref:

1581.0840001/RWE/M-G

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Fee Transmittal Form (PTO/SB/17);
- 2. Request for Continued Examination (RCE) Transmittal;
- 3. Amendment and Reply Under 37 C.F.R. § 1.111;
- Terminal Disclaimer to Obviate a Provisional Double Patenting Rejection 4. Over a Pending Second Application from Health Protection Agency;
- 5. Statement Under 37 C.F.R. § 3.73(b) from Health Protection Agency;
- 6. Terminal Disclaimer to Obviate a Provisional Double Patenting Rejection Over a Pending Second Application from Imperial College Innovations Ltd., with a copy of the Statement Under 37 C.F.R. § 3.73(b);
- 7. First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
- 8. Form PTO-1449 (2 sheets);
- 9. Copies of cited documents AB1, AC1, AS2, AT2, and AR3.

Sterne, Kessler, Goldstein & Fox P.L.C.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Commissioner for Patents October 28, 2004 Page 2

10. Credit Card Payment Form (PTO-2038) for \$900.00 to cover the following fees:

\$790.00

Request for continued examination fee (37 C.F.R. § 1.17(e));

\$110.00

Terminal disclaimer fee (37 C.F.R. § 1.20(d)); and

11. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert W. Esmond

Attorney for Applicants Registration No. 32,893

Enclosures

328399\_1.DOC